MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

MC

471.05

-0.04%↓

SANES

7.059

+0.26%↑

BNP

78.09

+1.13%↑

ALV

354.5

+0.25%↑

MUV2

575.8

+0.07%↑

Search

Bayer AG

Chiusa

SettoreFinanza

26.36 -0.17

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

26.185

Massimo

26.54

Metriche Chiave

By Trading Economics

Entrata

1.6B

1.3B

Vendite

2B

14B

P/E

Media del settore

30.9

24.968

EPS

2.49

Rendimento da dividendi

0.44

Margine di Profitto

9.492

Dipendenti

90,885

EBITDA

1.9B

3.6B

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+0.53% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.44%

4.18%

Utili prossimi

5 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

3.5B

25B

Apertura precedente

26.53

Chiusura precedente

26.36

Notizie sul Sentiment di mercato

By Acuity

37%

63%

139 / 538 Classifica in Finance

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Bayer AG Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 mag 2025, 08:22 UTC

Utili
I principali Market Mover

Bayer Shares Jump After Results Beat Expectations on Pharma Strength

13 mag 2025, 06:09 UTC

Utili

Bayer Confirms Guidance Despite Net Profit Drop

24 mar 2025, 09:37 UTC

I principali Market Mover

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

5 giu 2025, 08:29 UTC

Discorsi di Mercato

Bayer Earnings Expectations Might Have Bottomed out -- Market Talk

30 mag 2025, 13:47 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Consumer Health Sector Has Room for More Dealmaking -- Market Talk

27 mag 2025, 12:22 UTC

Discorsi di Mercato
Utili

Bayer's Prospects Are Improving -- Market Talk

16 mag 2025, 13:42 UTC

Azioni calde

Stocks to Watch Friday: Charter, Novo Nordisk, Applied Materials -- WSJ

16 mag 2025, 08:57 UTC

Azioni calde

Stocks to Watch Friday: Richemont, Bayer, Take-Two, UnitedHealth -- WSJ

15 mag 2025, 22:46 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mag 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 mag 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 mag 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

13 mag 2025, 06:50 UTC

Discorsi di Mercato
Utili

Bayer's Results Should Cause Positive Share Price Response -- Market Talk

13 mag 2025, 05:36 UTC

Utili

Bayer: Sees EBITDA Margin Before Special Items of Pharma Division to Come in at Upper End of Guidance Range

13 mag 2025, 05:35 UTC

Utili

Bayer: Sees Sales Growth of Pharma Division to Come in at Upper End of Guidance Range

13 mag 2025, 05:34 UTC

Utili

Bayer: Currency Adjusted Basis Guidance Includes Impact From Tariffs

13 mag 2025, 05:34 UTC

Utili

Bayer: Considerable Uncertainty Persists Concerning Future Impacts From Tariffs

13 mag 2025, 05:32 UTC

Utili

Bayer 1Q EPS EUR2.49

13 mag 2025, 05:32 UTC

Utili

Analysts Saw 1Q Ebitda Before Special Items at EUR3.82B

13 mag 2025, 05:32 UTC

Utili

Bayer 1Q Ebitda Before Special Items EUR4.085B

13 mag 2025, 05:31 UTC

Utili

Bayer 1Q EBIT EUR2.32B

13 mag 2025, 05:31 UTC

Utili

Bayer 1Q Net Pft EUR1.30B

13 mag 2025, 05:31 UTC

Utili

Analysts Saw Bayer 1Q Net Pft at EUR1.485B

13 mag 2025, 05:30 UTC

Utili

Analysts Saw Bayer 1Q Sales at EUR13.41B

13 mag 2025, 05:30 UTC

Utili

Bayer 1Q Sales EUR13.74B

13 mag 2025, 05:30 UTC

Utili

Bayer Backs 2025 View

14 apr 2025, 13:00 UTC

Notizie principali

Farmers' Favorite Weedkiller Nears Its End, Bayer Warns -- WSJ

7 apr 2025, 17:01 UTC

Discorsi di Mercato

Bayer Moves Forward in U.S. Roundup Litigation -- Market Talk

2 apr 2025, 09:27 UTC

Azioni calde

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

10 mar 2025, 08:38 UTC

Discorsi di Mercato

Bayer's Partial Recovery Is in Sight -- Market Talk

Confronto tra pari

Modifica del prezzo

Bayer AG Previsione

Obiettivo di Prezzo

By TipRanks

0.53% in crescita

Previsioni per 12 mesi

Media 26.58 EUR  0.53%

Alto 33 EUR

Basso 20 EUR

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Bayer AG - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

13 ratings

3

Acquista

10

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

22.99 / 23.88Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

139 / 538 Classifica in Finanza

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.